Skip to content
value.today
Denali Therapeutics Inc. logo

Denali Therapeutics Inc.

Denali Therapeutics Inc. is listed today as Denali Therapeutics Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Denali Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2024$500 MPrivate placement after listing$250 million to $1 billion

Denali Therapeutics Inc.: Private sale, Feb 2024

Investors in this round

11 investors had bought by the notice of Mar 1, 2024: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Denali Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$500 M of $500 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander O. Schuth · Executive Officer
  • Carole O. Ho · Executive Officer
  • Ryan Watts · Executive Officer, Director
  • David P. Schenkein · Director
  • Erik T. Harris · Director
  • Jay T. Flatley · Director
  • Jennifer O. Cook · Director
  • Marc P. Tessier-Lavigne · Director
  • Nancy A. Thornberry · Director
  • Peter S. Klein · Director
  • Steve E. Krognes · Director
  • Vicki L. Sato · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ryan Watts, President and CEO. Source: SEC Form D, newest notice filed Mar 1, 2024. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Denali Therapeutics Inc., its revenue in fiscal 2023 came from these business segments: Therapeutics $330.53 million (100%).

    Annual report (SEC XBRL) · Dec 2023

  • Denali Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2024).

    SEC Form D · Mar 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2024

Products and services#

No products or services of Denali Therapeutics Inc. are on record.

Investors#

17 named in official filings. Open an investor to see everything it has backed.

Investors in Denali Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Akdl, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
ARCH Venture Fund VIII, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
ARCH Venture Partners VIII, LLCVenture capitalnot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
ARCH Venture Partners VIII, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Bratton Capital Inc.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Bratton Capital Management, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Crestline Investors, Inc.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Crestline Management, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Crestline SI (GP), L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
FIL LtdFund or asset managernot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Flagship Ventures Fund V General Partner LLCVenture capitalnot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Flagship Ventures Fund V, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Fmr LLCFund or asset managernot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Marc Tessier-LavignePersonnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2017)SEC Form 3
Neuro Line Partners LPFund or asset managernot statednot statedHeld Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Ryan J. WattsPersonnot statednot statedHeld Series B-1 preferred stock, director (Form 3, 2017)SEC Form 3
Vicki L. SatoPersonnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Denali Therapeutics Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Denali Therapeutics Inc.
NameRoleNamed in
Alexander O. SchuthExecutive officerMar 2024
Carole O. HoExecutive officerMar 2024
Ryan WattsExecutive officerMar 2024
David P. SchenkeinDirectorMar 2024
Erik T. HarrisDirectorMar 2024
Jay T. FlatleyDirectorMar 2024
Jennifer O. CookDirectorMar 2024
Marc P. Tessier-LavigneDirectorMar 2024
Nancy A. ThornberryDirectorMar 2024
Peter S. KleinDirectorMar 2024
Ryan WattsDirectorMar 2024
Steve E. KrognesDirectorMar 2024
Vicki L. SatoDirectorMar 2024

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.